ImmuPharma PLC (IMM) Stock Rating Reaffirmed by Northland Securities
ImmuPharma PLC (LON:IMM)‘s stock had its “corporate” rating reaffirmed by equities research analysts at Northland Securities in a research note issued to investors on Wednesday.
A number of other research analysts have also issued reports on the company. Panmure Gordon reiterated a “buy” rating and issued a GBX 100 ($1.33) target price on shares of ImmuPharma PLC in a report on Tuesday, June 14th. Northland Capital Partners initiated coverage on ImmuPharma PLC in a report on Wednesday, July 20th. They issued a “buy” rating and a GBX 171 ($2.28) target price for the company.
Shares of ImmuPharma PLC (LON:IMM) traded down 0.65% during mid-day trading on Wednesday, hitting GBX 38.50. The stock had a trading volume of 148,877 shares. ImmuPharma PLC has a 52-week low of GBX 19.10 and a 52-week high of GBX 48.88. The firm has a 50 day moving average price of GBX 37.58 and a 200 day moving average price of GBX 32.68. The firm’s market cap is GBX 46.89 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/14/immupharma-plc-imm-stock-rating-reaffirmed-by-northland-securities.html
ImmuPharma PLC Company Profile
ImmuPharma plc (ImmuPharma) is a United Kingdom-based is a drug discovery and development company. Its research operations are in France. The Company is engaged in the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions, such as autoimmune diseases. ImmuPharma is engaged in developing drug candidates for five different medical conditions.
Receive News & Ratings for ImmuPharma PLC Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for ImmuPharma PLC and related companies with MarketBeat.com’s FREE daily email newsletter.